Top in cardiology: HFpEF and COVID-19, omega-3 fatty acid supplements

Researchers found evidence that COVID-19 may increase the risk for heart failure with preserved ejection fraction, or HFpEF. It was the top story in cardiology last week.

Another top story was about a study that showed omega-3 fatty acid supplementation may reduce the risk for some CVD outcomes.

Read these and more top stories in cardiology below:

COVID-19 may increase risk for HFpEF

There may be a link between COVID-19 and HFpEF, as infection from SARS-CoV-2 may cause, unmask or exacerbate HFpEF, according to a viewpoint published in JAMA. Read more.

Omega-3 fatty acid supplementation may reduce risk for certain CVD outcomes

Supplementation with eicosapentaenoic acid and docosahexaenoic acid may reduce the risk for some CVD outcomes, including fatal MI and CHD events, researchers found. Read more.

Artificial intelligence continues to evolve in cardiology

Artificial intelligence continues to affect cardiology with improved capabilities to diagnose certain conditions such as atrial fibrillation, and research is underway to learn more about its use in disease management. Read more.

AHA: SGLT2 inhibitors, GLP-1 receptor agonists offer cardiorenal protection

Trials of SGLT2 inhibitors and GLP-1 receptor agonists, typically treatments for type 2 diabetes, have demonstrated potential cardiovascular and kidney benefits, according to a scientific statement from the American Heart Association. Read more.

CHD prevention may improve productivity, GDP

Prevention of congenital heart disease may not only prolong life years, but it may also improve productivity, leading to improvement in gross domestic product, researchers reported. Read more.